Weiss Ratings Reiterates "Hold (C)" Rating for Grifols (NASDAQ:GRFS)

Key Points

• Weiss Ratings has reiterated a "hold (C)" rating for Grifols (NASDAQ:GRFS) in a research note issued to investors.
• JPMorgan Chase & Co. raised their target price on Grifols to $10.30 and assigned a "neutral" rating, while other analysts continue to give mixed ratings, resulting in a consensus rating of "Moderate Buy".
• Grifols has experienced significant trading activity, with several institutional investors increasing their positions in the stock during the second quarter of the year.

Grifols (NASDAQ:GRFS - Get Free Report)'s stock had its "hold (c)" rating reiterated by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. raised their target price on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a report on Tuesday, June 17th. Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a report on Tuesday, August 5th. Finally, Zacks Research raised Grifols to a "hold" rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $10.30.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $9.63 on Wednesday. Grifols has a 1-year low of $6.19 and a 1-year high of $11.14. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95. The stock has a fifty day moving average price of $10.08 and a 200 day moving average price of $8.85. The company has a market cap of $6.62 billion, a PE ratio of 8.23, a P/E/G ratio of 0.33 and a beta of 0.69.

Institutional Trading of Grifols

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Grifols by 2.4% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company's stock worth $427,000 after purchasing an additional 1,114 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in Grifols by 4.9% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 62,991 shares of the biotechnology company's stock worth $569,000 after purchasing an additional 2,928 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 3,399 shares in the last quarter. Cerity Partners LLC increased its position in Grifols by 22.8% during the 1st quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company's stock worth $158,000 after purchasing an additional 4,129 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in Grifols by 127.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company's stock worth $74,000 after purchasing an additional 4,604 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.